Recebido em 23/9/08; aceito em 21/1/09; publicado na web em 14/7/09 A series of 13 compounds analogous of isoniazid condensed with carbohydrate was synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H 37 Rv using Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC 90 ) in µg/mL. Several compounds exhibited antitubercular activity (0.31-3.12 µg/mL) when compared with first line drugs such as isoniazid (INH) and rifampicin (RIP) and could be a good starting point to develop new compounds against tuberculosis.
INTRODUCTION
Tuberculosis (TB), as declared by the World Health Organization (WHO) in 1993 has become a global health problem. This infectious disease is transmitted through the air by a Gram-positive bacterium Mycobacterium tuberculosis, which was first identified in 1882 by the German scientist Robert Koch (1843-1910).
1,2 TB mainly affects the lungs (pulmonary TB), but in over 15% of patients this bacterium could infect different parts of the body, such as the brain, stomach, bones, skin, intestine, liver, kidneys, spinal cord and breasts. In general, TB disease in these parts of the body occurs more frequently in children and in people with a weak immune system, such as people infected by the Human Immunodeficiency Virus (HIV). Normally, the symptoms of pulmonary TB are chronic cough (for more than two weeks), coughing up of blood, weight loss, fever, pain in the chest, fatigue and sweating at night. [3] [4] [5] Nowadays, according to statistics, TB kills four people every minute somewhere in the world and accounts about two million deaths per year. It is estimated that one-third of the world's population is currently infected with the TB bacillus and 30 million people will die in the next 10 years. 6 At present, the treatment against TB involves three or four different kinds of antibacterial drugs given in combination over six to nine months. These are isoniazid (INH), pyrazinamide (PZA), ethambutol (EMB) and rifampicin (RIP) (Figure 1 ). 7 Multiple combinations are necessary to prevent the emergence of multidrug resistant strains (MDR), which would lead to treatment failure.
Isonicotinic acid hydrazide or isoniazid (INH, see Figure 1 ) is one the more powerful synthetic agent against the M. tuberculosis complex and its minimum inhibitory concentration (MIC) is very low (0.1-0.7µM). 8 In the search of new compounds, isoniazid derivatives have been found to possess potential antitubercular activities. 9, 10 Studies suggest that isoniazid, a prodrug which is converted into its active form by mycobacterial catalase-peroxidase, acts on the mycobacterial cell wall by preventing the FAS-II (fatty acid synthetase II) system from producing long chain fatty acid precursors for mycolic acid synthesis.
11-14 Ventura and Martins 14 postulated that the activation of isoniazid derivatives' prodrugs occurs near the surface of M. tuberculosis.
In this context, due to the growth of MDR-TB and extensively drug-resistant tuberculosis XDR-TB, which are strains resistant to first and second line anti-TB drugs, we urgently need new drugs and strategies to fight efficiently against this disease.
Fox 15 described the preparation of some aldohexose, aldopentose, and fructosyl derivatives of isoniazid. This author claimed that these compounds are very active and relatively atoxic in mouse tuberculosis, although no biological data are furnished. Bernstein and co-workers 16 reported the synthesis of isonicotinyl hydrazones from L-arabinose, D-glucose, and D-galactose and others sugars not described in the present article. Little information about structural elucidation, conformation and biological activity was reported in these papers.
Considering the fundamental presence of carbohydrate, such as peptidoglycan and arabinogalactan, in the construction of the mycobacterial cell walls [17] [18] [19] and the reaction between INH and aldehydes (e.g. glucose and lactose) in drug formulations, 20 in this work we 
RESULTS AND DISCUSSION
The preparation of the compounds described in this work involved the reaction between isoniazid and appropriate carbohydrates in methanol at reflux, leading to the desired compounds 1-13 in 20-75% yields (Scheme 1). Aldehyde 14 was prepared from D-glucose in three steps and treated with isoniazid to furnish the corresponding hydrazone 7 (Scheme 1). All the compounds were identified by spectral data and although one major peak was usually observed, there were 1-3 additional peaks for each compound. The molecules were found to exist primarily as cyclic products. The conformations were assigned based on J couplings of ring protons and the relatively upfield chemical shifts of H-1 for the cyclic compounds. In the hexose series it was observed that the 2-isonicotinoylhydrazine function favors an equatorial orientation and the pyranose rings forms were dominant. 21 For example, with the D-glucose 1 and D-galactose 5 derivatives only the β-pyranosyl form ( 4 C 1 conformation) was observed.
11,12 The 2-isonicotinoylhydrazine function was also equatorially disposed in the L-fucosyl and L-rhamnosyl products which, by nomenclature convention, 22 were the 1 C 4 conformer. For the L-series derivatives the pyranosyl form ( 1 C 4 conformation) was found as the major product. In the pentose series, the products from D or L-arabinose, 8 and 11 respectively, and Lribose 12 were obtained as a mixture of cyclic and open-chain form products.
In general, IR spectra showed the OH peaks at 3460-3370 cm 
Biological evaluation
The antimycobacterial activities of compounds 1-13 were assessed against M. tuberculosis ATTC 2729 23 using the micro plate Alamar Blue assay (MABA) 24 (Table 1 ). This methodology is nontoxic, uses thermally-stable reagents and shows good correlation with proportional and BACTEC radiometric methods. 25, 26 Briefly, two hundred microliters of sterile deionized water was added to all outer-perimeter wells of sterile 96 well plates (Falcon, 3072: Becton Dickinson, Lincoln Park NJ) to minimize evaporation of the medium in the test wells during incubation. The 96 plates received 100 µL of the Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI, USA) and a serial dilution of the compounds was made directly on the plate. The final drug concentrations tested were 0.01 to 10.0 µL /mL. Plates were covered and sealed with parafilm and incubated at 37 o C for five days. After this time, 25 µL of a freshly prepared 1:1 mixture of Alamar Blue (Accumed International, Westlake Ohio) reagent and 10% Tween 80 were added to the plate and incubated for twenty-four hours. A blue color in the well was interpreted as absence of bacterial growth and a pink color was scored as growth. The MIC (Minimal Inhibition Concentration) was defined as the lowest drug concentration to give 90% inhibition of bacterial growth, which prevented a color change from blue to pink.
The results show that some compounds exhibited activity against M. tuberculosis. The best results were obtained with the mixture of compounds 11a and 11b, in equilibrium, that exhibited a MIC 90 of 0.31 µg/mL (Table 1) . Compounds 1, 2, 5, 6, 7, 9, 10 and 13 exhibited activity between 0.62 and 3.12 µg/mL when compared with first line drugs such as isoniazid (INH) and rifampin (RIP).
Scheme 1. Preparation of isoniazid derivatives

CONCLUSION
In conclusion, the preliminary antimycobacterial activities study of 13 compounds based on the coupling of isoniazid with different carbohydrates described here suggest that they may be selectively targeted to M. tuberculosis growth. The compounds exhibited activity against M. tuberculosis H 37 Rv (ATTC 27294) in the range 0.31-3.12 µg/mL when compared with first line drugs such as isoniazid (INH) and rifampicin (RIP), and could be a good starting point for further studies as well as find new lead compounds.
EXPERIMENTAL
General procedures
Melting points were determined on a Tomas-Hoover apparatus and are uncorrected. Infrared spectra were recorded on a Bomem-FTIR MB-102 spectrometer and frequencies are expressed in cm -1 . Mass spectra were obtained with a Maldi-Tof instrument for high resolution mass spectra (HREIMS). NMR spectra were recorded on a Bruker Avance spectrometer operating at 300.00 MHz ( 1 H) and 75.0 MHz ( 13 C), in deuterated water. Chemical shifts are reported in ppm (δ) relative to tetramethylsilane. Proton and carbon spectra were typically obtained at room temperature. The aldehyde 14 was prepared in three steps from D-glucose. 27, 28 General procedure for the preparation of derivatives 1-13
To a solution of the isoniazid (4.2 mmol, 1.5 equiv.) in methanol (20 mL) at 60 °C was added (2.8 mmol) of the carbohydrate. The reaction mixture was stirred at this temperature for 24 h and the solid formed was filtered and washed with warmed methanol. The solid obtained was recrystallized in a mixture of methanol/water to furnish compounds 1, 5, 6, 8, 9, 10 and 11. For compounds 2, 3, 4, 12 and 13 the purification was realized by chromatography using as eluent a gradient of ethyl acetate and methanol. 03 (m, 12H, H-2', H-3', H-4', H-5', H-6'a, H-6'b, H-2'', H-3'',  H-4', H-5'', H-6''a, H-6''b), 4.32 (d, 1H, H-1' J 9.0Hz), 4.49 (d, 1H , C-4' ), 70.9 (C-2'), 76.6 (C-3'), 90.8 (C-1'), 122.0 (C-3, C-5), 140.9 (C-4), 149.7 (C-2, C-6), 168.1 (C=O).
1-(1'-β-D-Glucopyranosyl)-2-isonicotinoyl-hydrazine
1-(1'-β-D-Mannopyranosyl)-2-isonicotinoyl-hydrazine
1-(1'-β-D-2'-Acetamido-2'-deoxy-glucopyranosyl)-2-isonicotinoyl-
1-(1'-β-D-2'-Acetamido-2'-deoxy-mannopyranosyl)-2-isonicotinoylhydrazine 4 (α and β isomers)
1-(1'β-D-Lactosylpyranosyl)-2-isonicotinoyl-hydrazine
1-(1'-β-L-Ramnopyranosyl)-2-isonicotinoyl-hydrazine
